Gilead Sciences Inc. (NASDAQ:GILD) Belonging to the Medical sector which surged 1.62% and closed its last trading session at $79.12.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 10/25/2016. Currently, the stock has a 1 Year Price Target of $103.5.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.06 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.06 and 1.94 respectively.
Gilead Sciences Inc. on 6/30/2016 reported its EPS as $3.08 with the analysts projecting the EPS of the stock as $3.02. The company beat the analyst EPS Estimate with the difference of $0.06. This shows a surprise factor of 2%.
Many analysts have provided their estimated foresights on Gilead Sciences Inc. Earnings, with 22 analysts believing the company would generate an Average Estimate of $2.88. Whereas they predicted High and Low Earnings Estimate as $3.11 and $2.63 respectively. While in the same Quarter Previous year, the Actual EPS was $3.22.
Analysts are also projecting an Average Revenue Estimate for Gilead Sciences Inc. as $7.52 Billion in the Current Quarter. This estimate is provided by 19 analysts. The High Revenue estimate is predicted as 7.98 Billion, while the Low Revenue Estimate prediction stands at 7.22 Billion. The company’s last year sales total was 8.3 Billion.
For the Current Quarter, the growth estimate for Gilead Sciences Inc. is -10.6%, while for the Next Quarter the stock growth estimate is -15.1%. In the past 5 years, the stock showed growth of 66.46% per annum. While for the next 5 years, the growth estimate is -0.21%.
The Company got Downgrade by Leerink Partners on 27-Sep-16 from Outperform to Mkt Perform.
Insider Trades for Gilead Sciences Inc. show that the latest trade was made on 21 Sep 2016 where Alton (Gregg H), the Officer completed a transaction type “Sell” in which 5000 shares were traded at a price of $81.84.
47 Insider Sales transactions were made totaling 2536300 shares traded.
18 analysts projected Price Targets for Gilead Sciences Inc. The analysts believe that the company stock price could grow as high as $122. The Low Price target projection by analysts is $80 and the Mean Price Target is $103.5.
Gilead Sciences Inc. (NASDAQ:GILD) has the market capitalization of $105.63 Billion. The company rocked its 52-Week High of $111.11 on Oct 27, 2015 and touched its 52-Week Low of $76.67 on Sep 2, 2016. The stock has Return on Assets (ROA) of 32.7 percent. Return on Equity (ROE) stands at 100.8% and Return on Investment (ROI) of 45.9 percent.
The stock is currently showing YTD performance of -20.51 Percent. The company has Beta Value of 1.11 and ATR value of 1.38. The Weekly and Monthly Volatility stands at 1.69% and 1.59%.
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.